Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
PRPROCEPT BioRobotics Corporation logo

PROCEPT BioRobotics Corporation (PRCT)

NASDAQ Global Market · Currency in USD
$19.96 ▼ -0.07 (-0.35%)
At close: Oct 23, 4:00 PM ET. Market closed.
$20.17 ▲ +0.21 (+1.05%)
After hours: Oct 23, 7:59 PM ET

Summary

Previous Close
$20.03
Open
$19.90
Day's Range
$19.58 – $20.12
52 Week Range
$16.67 – $38.11
Volume
773,745
Avg. Volume
1,464,205
Market Cap
$1.14B
Beta (5Y Monthly)
0.92
PE Ratio (TTM)
--
EPS (TTM)
-$1.94
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$23.00

Profile: PROCEPT BioRobotics Corporation

Sector
Healthcare
Industry
Medical - Devices
Full-time employees
888
CEO
Larry L. Wood

PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH).

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate -$0.39 · Revenue est. $100.52M
DateEst.Actual
Aug 4, 2026-$0.46-$0.47Miss
Apr 29, 2026-$0.55-$0.56Miss
Feb 25, 2026-$0.32-$0.53Miss
Nov 4, 2025-$0.41-$0.38Beat
Aug 6, 2025-$0.41-$0.35Beat
Apr 24, 2025-$0.49-$0.45Beat

Analyst view

Consensus price target
$23.00 ▲ +15.2%
Range $19.00 – $30.00
Rating: Buy
Buy 56% · Hold 38% · Sell 6%

Get free alerts on PRCT and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.